{
    "doi": "https://doi.org/10.1182/blood.V122.21.5238.5238",
    "article_title": "Possible Role Of Treatment On Secondary Malignancies In Patients Affected By Essential Thrombocytemia ",
    "article_date": "November 15, 2013",
    "session_type": "634. Myeloproliferative Syndromes: Clinical",
    "abstract_text": "Introduction Survival of Essential Thrombocytemia (ET) patients in the first 10 years of disease follow-up is similar to the general population one. While it is well known that alkylating agents (given alone or sequentially) increase the risk for acute myeloid leukemia, the specific role of different therapies on the development of secondary malignancies (SM) in ET patients, is still under investigation. Aims To retrospectively evaluate the role of different treatments on the development of SM in a large population of ET patients. Patients and methods We collected a series of 1026 ET patients (diagnosis period 1980-2010), followed in 11 Hematological Centers (universities 5, general hospitals 6) from the region Lazio in Central Italy. Median age at ET diagnosis is 62.5 years (range 17-93); 392 males, 634 females; median follow-up of the entire population is 6.2 years (range 0.1 \u2013 31.9). Seventy/1026 patients (6.8%) developed 71 SM during follow-up. \u00a0Observed SM were grouped as follows: genito-urinary 15, breast 14, non-melanoma skin cancer 12, lung 11, gastro-intestinal 8, hematologic 5, thyroid 3, central nervous system 1, soft tissue 1 and unknown 1. Taking in consideration the different treatment approach, we divided our population in 5 different groups: group 0, no treated patients; group 1, patients treated either with Hydroxiurea (HU) alone or in combination/sequentially\u00a0 with Interpheron (IFN)/Anagrelide (ANA); group 2, patients treated either with alkylating agents (ALK) alone or in combination/sequentially\u00a0 with IFN/ANA; group 3, patients treated with ALK + HU sequentially; group 4,\u00a0 patients treated with ANA and/or IFN only. Characteristics of the patients are shown in the table.  . GROUP 0 NO THERAPY . GROUP 1 HU . GROUP 2 ALK . GROUP 3 ALK + HU . GROUP 4 ANA /IFN . Secondary malignancy (SM) Yes No Yes No Yes No Yes No Yes No Number (%) 11 (5) 209 46 (7.1) 595 4 (15.4) 22 8 (9.3) 78 2 (3.8) 51 Gender(M/F) 4/7 80/129 26/20 224/371 3/1 11/11 3/5 26/52 2/0 13/38 Median age at ET diagnosis (years) 67 (39-72) 47 (17-83) 69.5 (41-90) 67 (21-96) 63.5 (40-76) 62 (33-85) 61.5 (32-80) 62 (31-85) 63 34 (21-83) Median period between ET diagnosis and treatment start (years) NA NA 0.1 (0-11) 0.2 (0-18) 0.3 (0.1-6.6) 0.2 (0-1.6) 0.3 (0-1.6) 0.2 (0-13) 0 1.4 (0-10.2) Median period between ET diagnosis and SM diagnosis (years) 4.1 (0.7-15) NA 5.9 (0.2-22.4) NA 9.9 (3-28) NA 9.7 (1.6-21.3) NA 13.5 (9.1-17.9) NA Median period between treatment start and SM diagnosis (years) NA NA 4.7 (0.1-22.4) NA 9.6 (2.9-21.5) NA 8.2 (1.6-21.3) NA 13.5 (9.1-17.9) NA Median period of drug exposure (years) NA NA 5.6 (0.2-18.5) 4.0 (0.1-30.4) 5.5 (0.9-17) 8.8 (0.4-23.4) 14.7 (2.3-21) 8.7 (0.6-24.2) 13.3 3.1 (0.1-19.8) . GROUP 0 NO THERAPY . GROUP 1 HU . GROUP 2 ALK . GROUP 3 ALK + HU . GROUP 4 ANA /IFN . Secondary malignancy (SM) Yes No Yes No Yes No Yes No Yes No Number (%) 11 (5) 209 46 (7.1) 595 4 (15.4) 22 8 (9.3) 78 2 (3.8) 51 Gender(M/F) 4/7 80/129 26/20 224/371 3/1 11/11 3/5 26/52 2/0 13/38 Median age at ET diagnosis (years) 67 (39-72) 47 (17-83) 69.5 (41-90) 67 (21-96) 63.5 (40-76) 62 (33-85) 61.5 (32-80) 62 (31-85) 63 34 (21-83) Median period between ET diagnosis and treatment start (years) NA NA 0.1 (0-11) 0.2 (0-18) 0.3 (0.1-6.6) 0.2 (0-1.6) 0.3 (0-1.6) 0.2 (0-13) 0 1.4 (0-10.2) Median period between ET diagnosis and SM diagnosis (years) 4.1 (0.7-15) NA 5.9 (0.2-22.4) NA 9.9 (3-28) NA 9.7 (1.6-21.3) NA 13.5 (9.1-17.9) NA Median period between treatment start and SM diagnosis (years) NA NA 4.7 (0.1-22.4) NA 9.6 (2.9-21.5) NA 8.2 (1.6-21.3) NA 13.5 (9.1-17.9) NA Median period of drug exposure (years) NA NA 5.6 (0.2-18.5) 4.0 (0.1-30.4) 5.5 (0.9-17) 8.8 (0.4-23.4) 14.7 (2.3-21) 8.7 (0.6-24.2) 13.3 3.1 (0.1-19.8) NA: not applicable View Large Results and conclusions Taking into account every single treatment group, although we observed an increased rate in the ALK one (4/26, 15.4%), we could not find a statistically significant difference in the risk of SM development. Instead, combining\u00a0 different groups we obtained the subsequent results: group 0 + 4 versus group 1, no statistically significant difference (p= 0.174); group 0 + 4 versus 2 + 3 statistically significant difference (p= 0.031). Compared to anagrelide, interferon or no treatment, alkylating agents alone or given \u00a0sequentially with hydroxiurea, seem to increase the risk of SM development,\u00a0 while HU treatment alone do not. Disclosures: No relevant conflicts of interest to declare.",
    "topics": [
        "neoplasm metastasis",
        "thrombocythemia, hemorrhagic",
        "alkylating agents",
        "follow-up",
        "anagrelide",
        "human leukocyte interferon",
        "interferons",
        "leukemia, myelocytic, acute",
        "melanoma",
        "nitric oxide therapy"
    ],
    "author_names": [
        "Cristina Santoro, M.D.",
        "Jonny Di Giandomenico",
        "Marianna De Muro",
        "Nicoletta Villiv\u00e0",
        "Ambra Di Veroli, MD",
        "Marco Montanaro, MD",
        "Roberto Latagliata, MD",
        "Barbara Anaclerico",
        "Giuseppe Avvisati, MD, PhD",
        "Massimo Breccia",
        "Michele Cedrone",
        "Giuseppe Cimino, MD",
        "Guido Montanaro, MD",
        "Enrico Montefusco",
        "Stefano Felici",
        "Sabrina Leonetti Crescenzi",
        "Ignazio Majolino",
        "Prof",
        "Raffaele Porrini",
        "Angela Rago, MD",
        "Antonio Spadea",
        "Francesca Spirito, MD",
        "Giuliana Alimena",
        "Maria Gabriella Mazzucconi, MD",
        "Alessandro Andriani"
    ],
    "author_dict_list": [
        {
            "author_name": "Cristina Santoro, M.D.",
            "author_affiliations": [
                "Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy, "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Jonny Di Giandomenico",
            "author_affiliations": [
                "Hematology, Tor Vergata University, Rome, Italy, "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Marianna De Muro",
            "author_affiliations": [
                "Hematology, Campus Biomedico University, Rome, Italy, "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Nicoletta Villiv\u00e0",
            "author_affiliations": [
                "Hematology, Nuovo Regina Margherita Hospital, Rome, Italy, "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ambra Di Veroli, MD",
            "author_affiliations": [
                "Hematology, Tor Vergata University, Rome, Italy, "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Marco Montanaro, MD",
            "author_affiliations": [
                "ASL VT, UOC of Hemathology, Viterbo, Italy, "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Roberto Latagliata, MD",
            "author_affiliations": [
                "Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy, "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Barbara Anaclerico",
            "author_affiliations": [
                "Hematology, Azienda Ospedaliera S.Giovanni Addolorata, Rome, Italy, "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Giuseppe Avvisati, MD, PhD",
            "author_affiliations": [
                "Hematology, Campus Biomedico University, Rome, Italy, "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Massimo Breccia",
            "author_affiliations": [
                "Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy, "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Michele Cedrone",
            "author_affiliations": [
                "Hematology, Azienda Ospedaliera S.Giovanni Addolorata, Roma, Italy, "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Giuseppe Cimino, MD",
            "author_affiliations": [
                "Hematology, Sapienza University, Polo Pontino, Rome, Italy, "
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Guido Montanaro, MD",
            "author_affiliations": [
                "ASL VT, UOC of Hemathology, Viterbo, Italy, "
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Enrico Montefusco",
            "author_affiliations": [
                "Hematology, Sant'Andrea Hospital, Rome, Italy, "
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Stefano Felici",
            "author_affiliations": [
                "Hematology, Nuovo Regina Margherita Hospital, Rome, Italy, "
            ],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Sabrina Leonetti Crescenzi",
            "author_affiliations": [
                "Sandro Pertini Hospital, Hematology, Rome, Italy, "
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ignazio Majolino",
            "author_affiliations": [],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Prof",
            "author_affiliations": [
                "HEMATOLOGY AND STEM CELL TRANSPLANTATION, SAN CAMILLO FORLANINI HOSPITAL, ROME, Italy, "
            ],
            "author_rank": 18,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Raffaele Porrini",
            "author_affiliations": [
                "Hematology, Sant'Andrea Hospital, Rome, Italy, "
            ],
            "author_rank": 19,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Angela Rago, MD",
            "author_affiliations": [
                "Hematology, Sapienza University, Polo Pontino, Latina, Italy, "
            ],
            "author_rank": 20,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Antonio Spadea",
            "author_affiliations": [
                "Regina Elena National Cancer Institute, Hematology, IFO, Rome, Italy, "
            ],
            "author_rank": 21,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Francesca Spirito, MD",
            "author_affiliations": [
                "HEMATOLOGY AND STEM CELL TRANSPLANTATION, SAN CAMILLO FORLANINI HOSPITAL, ROME, Italy, "
            ],
            "author_rank": 22,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Giuliana Alimena",
            "author_affiliations": [
                "Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy, "
            ],
            "author_rank": 23,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maria Gabriella Mazzucconi, MD",
            "author_affiliations": [
                "Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy, "
            ],
            "author_rank": 24,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Alessandro Andriani",
            "author_affiliations": [
                "Hematology, Nuovo Regina Margherita Hospital, Roma, Italy"
            ],
            "author_rank": 25,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-25T06:44:52",
    "is_scraped": "1"
}